4.8 Article

Parahydrogen in Reversible Exchange Induces Long-Lived 15N Hyperpolarization of Anticancer Drugs Anastrozole and Letrozole

期刊

ANALYTICAL CHEMISTRY
卷 95, 期 20, 页码 7822-7829

出版社

AMER CHEMICAL SOC
DOI: 10.1021/acs.analchem.2c04817

关键词

-

向作者/读者索取更多资源

Hyperpolarization modalities, particularly SABRE, are employed to enhance 15N polarization of nitrile-containing anticancer drugs. Optimal parameters, including temperature, magnetic field, and field profile, are fine-tuned for different substrates. Over 10% hyperpolarization and 280,000-fold signal enhancement are achieved for letrozole and anastrozole. Prolonged polarization storage and signal detection are enabled by the nitrile 15N sites.
Hyperpolarization modalities overcome the sensitivity limitations of NMR and unlock new applications. Signal amplification by reversible exchange (SABRE) is a particularly cheap, quick, and robust hyperpolarization modality. Here, we employ SABRE for simultaneous chemical exchange of parahydrogen and nitrile-containing anticancer drugs (letrozole or anastrozole) to enhance 15N polarization. Distinct substrates require unique optimal parameter sets, including temperature, magnetic field, or a shaped magnetic field profile. The fine tuning of these parameters for individual substrates is demonstrated here to maximize 15N polarization. After optimization, including the usage of pulsed mu T fields, the 15N nuclei on common anticancer drugs, letrozole and anastrozole, can be polarized within 1-2 min. The hyperpolarization can exceed 10%, corresponding to 15N signal enhancement of over 280,000-fold at a clinically relevant magnetic field of 1 T. This sensitivity gain enables polarization studies at naturally abundant 15N enrichment level (0.4%). Moreover, the nitrile 15N sites enable long-lasting polarization storage with [15N]T1 over 9 min, enabling signal detection from a single hyperpolarization cycle for over 30 min.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据